Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 8/20 | 0.34 |
| ▸ | MAOA | P21397 | 8/20 | 0.34 |
| ▸ | MAOB | P27338 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568303 | 1.00 | CYP3A4 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A | |
| SCHEMBL25568302 | 0.89 | CYP3A4 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A | |
| SCHEMBL25568304 | 0.89 | CYP3A4 (0.42) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A | |
| SCHEMBL31251918 | 0.77 | SMN1; SMN2 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A | |
| SCHEMBL31252128 | 0.75 | CYP3A4 (0.43) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL29239690 | 0.74 | MAOA (0.38) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A | |
| SCHEMBL13103206 | 0.73 | SMYD2 (0.40) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL453430 | 0.73 | SMN1; SMN2 (0.44) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL15348146 | 0.72 | CYP3A4 (0.54) | CYP3A4HTTSMN1; SMN2SMYD2MAOB | |
| SCHEMBL10422986 | 0.71 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | CYP3A4 3234/4885HTT 3703/4885SMN1; SMN2 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.